Form 4: Ligand Pharmaceuticals Officer Sells Shares Under Pre-Planned Trading Program

Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals Inc., reported the sale of 500 shares of common stock as part of a Rule 10b5-1 trading plan.

Summary

• Andrew Reardon, the Chief Legal Officer and Secretary of Ligand Pharmaceuticals Inc. (LGND), sold 500 shares of the company's common stock.
• The transaction took place on June 23, 2025.
• The shares were sold at a price of $114.0843 per share.
• Following this transaction, Mr. Reardon directly beneficially owns 31,903 shares of Ligand Pharmaceuticals common stock.
• The sale was conducted pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-scheduled transaction.

Sentiment

Score: 5

Explanation: The document reports a routine insider stock sale by an officer, which is a factual transaction. The sale was conducted under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on new, non-public information, thus indicating a neutral sentiment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, which suggests the sale was pre-planned and not based on new, non-public information, often viewed favorably as it reduces the perception of opportunistic insider trading.

Negatives

• An insider selling shares, even if pre-planned, results in a reduction of their direct ownership stake in the company.

Risks

• While not a direct risk from this specific document, a pattern of significant insider selling across multiple executives could potentially signal a lack of confidence in future performance, though this single transaction does not indicate such a pattern.

Future Outlook

No forward-looking statements or guidance regarding the company's future performance or strategic direction are provided in this Form 4 filing, which solely reports an insider's securities transaction.

Industry Context

This Form 4 filing reports a routine insider stock transaction and does not contain information relevant to broader industry trends, competitive landscape, or market developments within the pharmaceutical or biotechnology sectors.

Stakeholder Impact

• Shareholders: The sale of 500 shares by an officer slightly reduces insider ownership. However, given the relatively small volume of shares sold compared to the company's total shares outstanding and the pre-planned nature of the transaction (Rule 10b5-1), the direct impact on shareholders is minimal and unlikely to signal a significant change in company prospects.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Andrew Reardon, SEC Form 4, Insider Trading, Stock Sale, Beneficial Ownership, Common Stock, Rule 10b5-1